84 related articles for article (PubMed ID: 3458430)
1. [Pharmacokinetics of epirubicin in cancer patients].
Ohno T; Shimoyama T; Kimura K; Yamada H
Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer.
Peterson C; Gunvén P; Theve NO
Cancer Treat Rep; 1986 Aug; 70(8):947-52. PubMed ID: 3460699
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of epirubicin after intravenous administration: experimental and clinical aspects.
Dine T; Luyckx M; Brunet C; Cazin M
Methods Find Exp Clin Pharmacol; 1991 Sep; 13(7):483-9. PubMed ID: 1784146
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of KRN 8602 in cancer patients].
Majima H; Shinkai H
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2589-95. PubMed ID: 1746971
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of isepamicin.
Barr WH; Colucci R; Radwanski E; Zampaglione N; Cutler D; Lin CC; Elliott M; Affrime MB
J Chemother; 1995 Jun; 7 Suppl 2():53-61. PubMed ID: 8622111
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of epirubicin.
Robert J
Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
17. Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
Martini A; Moro E; Pacciarini MA; Tamassia V; Natale N; Piazza E
Int J Clin Pharmacol Res; 1984; 4(3):231-8. PubMed ID: 6593309
[TBL] [Abstract][Full Text] [Related]
18. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
20. [The pharmacokinetics of doxorubicin].
Erttmann R; Grandt M; Erb N; Garbrecht M; Landbeck G
Klin Padiatr; 1986; 198(3):271-6. PubMed ID: 3723990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
